scispace - formally typeset
C

Charles A. Dinarello

Researcher at University of Colorado Denver

Publications -  1073
Citations -  152254

Charles A. Dinarello is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Interleukin & Cytokine. The author has an hindex of 190, co-authored 1058 publications receiving 139668 citations. Previous affiliations of Charles A. Dinarello include University of Guadalajara & Pennsylvania State University.

Papers
More filters
Journal ArticleDOI

Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF.

TL;DR: A specific radioimmunoassay was developed and used for IL-6 to compare production of this cytokine on a molar basis with that of IL-1 alpha,IL-1 beta, and tumor necrosis factor (TNF)alpha, and there was a significant correlation betweenIL-6 and IL-2 beta (r = .72) and between IL-4 and TNF ( r = .66).
Journal ArticleDOI

The Role of Interleukin-1 in Disease

TL;DR: The interleukin-1 stimulates the release of pituitary hormones, increases the synthesis of collagenases, resulting in the destruction of cartilage, and stimulates the production of prostaglandins, leading to a decrease in the pain threshold.
Journal ArticleDOI

Nucleotide sequence of human monocyte interleukin 1 precursor cDNA.

TL;DR: The cDNA nucleotide sequence suggests that IL-1 is initially translated as a precursor molecule that is subsequently processed into the 15,000-20,000 Mr protein usually associated with IL- 1 activity.
Journal ArticleDOI

Overview of the IL-1 family in innate inflammation and acquired immunity.

TL;DR: Although the inflammatory properties of the IL‐1 family dominate in innate immunity, IL‐2 family member can play a role in acquired immunity and this overview is a condensed update.
Journal ArticleDOI

IL-1 is required for tumor invasiveness and angiogenesis

TL;DR: The anti-angiogenic effects of IL-1 receptor antagonist, shown here, suggest a possible therapeutic role in cancer, in addition to its current use in rheumatoid arthritis.